CN1738806A - 氧代－氮杂双环化合物 - Google Patents

氧代－氮杂双环化合物 Download PDF

Info

Publication number
CN1738806A
CN1738806A CNA038048752A CN03804875A CN1738806A CN 1738806 A CN1738806 A CN 1738806A CN A038048752 A CNA038048752 A CN A038048752A CN 03804875 A CN03804875 A CN 03804875A CN 1738806 A CN1738806 A CN 1738806A
Authority
CN
China
Prior art keywords
compound
general formula
group
alkyl
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038048752A
Other languages
English (en)
Chinese (zh)
Inventor
伯纳德·高迪利尔
亨利·雅各贝利
凯瑟琳·科斯特兰
杰克·李
岳文松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1738806A publication Critical patent/CN1738806A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA038048752A 2002-03-08 2003-03-06 氧代－氮杂双环化合物 Pending CN1738806A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP02/03240 2002-03-08
PCT/EP2002/003240 WO2003076416A1 (fr) 2002-03-08 2002-03-08 Composes oxo azabicycliques

Publications (1)

Publication Number Publication Date
CN1738806A true CN1738806A (zh) 2006-02-22

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038048752A Pending CN1738806A (zh) 2002-03-08 2003-03-06 氧代－氮杂双环化合物

Country Status (25)

Country Link
EP (1) EP1492775A2 (fr)
JP (1) JP2005526070A (fr)
KR (1) KR20040095270A (fr)
CN (1) CN1738806A (fr)
AP (1) AP2004003125A0 (fr)
AR (1) AR039562A1 (fr)
AU (2) AU2002249275A1 (fr)
BR (1) BR0308280A (fr)
CA (1) CA2478706A1 (fr)
CO (1) CO5601020A2 (fr)
EA (1) EA200401053A1 (fr)
EC (1) ECSP045278A (fr)
IL (1) IL163818A0 (fr)
IS (1) IS7414A (fr)
MA (1) MA27183A1 (fr)
MX (1) MXPA04008681A (fr)
NO (1) NO20044041L (fr)
OA (1) OA12782A (fr)
PA (1) PA8568501A1 (fr)
PE (1) PE20031018A1 (fr)
PL (1) PL372622A1 (fr)
SV (1) SV2003001495A (fr)
TN (1) TNSN04169A1 (fr)
UY (1) UY27700A1 (fr)
WO (2) WO2003076416A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148376B2 (en) 2006-10-05 2012-04-03 Gilead Sciences, Inc. 3, 4-dihydroquinoxalin-2(1H)-ones for use as stearoyl CoA desaturase inhibitors
CN103524431A (zh) * 2013-09-24 2014-01-22 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
CN108495857A (zh) * 2016-01-14 2018-09-04 法国施维雅药厂 新的磷杂环己烷类化合物和氮杂磷杂环己烷类化合物，它们的制备方法和包含它们的药用组合物

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
MXPA05001783A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
WO2004014378A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice
WO2004014375A2 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloprotease bicycliques condenses
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
MXPA05001786A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
MXPA05001603A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
CA2497658A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de chromone inhibiteurs de metalloproteinase de matrice
WO2004014384A2 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Composes cycliques contenant des groupes liant le zinc en tant qu'inhibiteurs de metalloprotease de matrice
WO2005016926A1 (fr) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Derives de pyrido[3,4-d]pyrimidine utiles comme inhibiteurs de la metalloproteinase-13 de matrice
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
MXPA06012333A (es) * 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
WO2005123696A1 (fr) * 2004-06-15 2005-12-29 Astrazeneca Ab Quinazolones substitues en tant qu'agents anticancereux
WO2012052451A1 (fr) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs métabotropes au glutamate
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE050567T2 (hu) 2015-09-23 2020-12-28 Janssen Pharmaceutica Nv Triciklusos heterociklusok rák kezelésére
WO2017050865A1 (fr) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-hétéroaryle 1,4-benzodiazépines substituées et leurs utilisations pour le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9714222A (pt) * 1996-12-17 2000-04-18 Du Pont Método para o controle de doenças de plantas
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148376B2 (en) 2006-10-05 2012-04-03 Gilead Sciences, Inc. 3, 4-dihydroquinoxalin-2(1H)-ones for use as stearoyl CoA desaturase inhibitors
CN103524431A (zh) * 2013-09-24 2014-01-22 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
CN108495857A (zh) * 2016-01-14 2018-09-04 法国施维雅药厂 新的磷杂环己烷类化合物和氮杂磷杂环己烷类化合物，它们的制备方法和包含它们的药用组合物

Also Published As

Publication number Publication date
TNSN04169A1 (fr) 2007-03-12
CO5601020A2 (es) 2006-01-31
CA2478706A1 (fr) 2003-09-18
PE20031018A1 (es) 2004-01-09
NO20044041L (no) 2004-10-07
IS7414A (is) 2004-08-19
OA12782A (en) 2006-07-10
WO2003076416A1 (fr) 2003-09-18
UY27700A1 (es) 2003-10-31
MA27183A1 (fr) 2005-01-03
AU2002249275A1 (en) 2003-09-22
ECSP045278A (es) 2004-10-26
AP2004003125A0 (en) 2004-09-30
WO2003076417A2 (fr) 2003-09-18
BR0308280A (pt) 2004-12-28
AU2003212307A1 (en) 2003-09-22
JP2005526070A (ja) 2005-09-02
MXPA04008681A (es) 2004-12-06
IL163818A0 (en) 2005-12-18
KR20040095270A (ko) 2004-11-12
EA200401053A1 (ru) 2005-04-28
WO2003076417A3 (fr) 2003-11-13
PL372622A1 (en) 2005-07-25
SV2003001495A (es) 2003-11-04
EP1492775A2 (fr) 2005-01-05
AR039562A1 (es) 2005-02-23
PA8568501A1 (es) 2003-12-19

Similar Documents

Publication Publication Date Title
CN1088702C (zh) 二取代双环杂环,其制备法及作为药物的用途
CN1286822C (zh) 嘧啶酮化合物
CN1179952C (zh) 作为ldl-pla2抑制剂的嘧啶-4-酮衍生物
CN1033088C (zh) 新的噻唑基苯并呋喃衍生物的制备方法
CN1043639C (zh) 新的哌啶化合物、其制备方法和含有它们的药用组合物
CN1150195C (zh) 双环氮杂环
CN86106984A (zh) 新的喹唑啉衍生物及其制备方法
CN1197849C (zh) 作为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂草－3－异羟肟酸
CN87105680A (zh) 咪唑化合物及其制备方法，和包含该化合物的药物组合物
CN1675184A (zh) 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
CN1753670A (zh) 新苯并咪唑和咪唑并吡啶衍生物及其作为药物的用途
CN1344256A (zh) (杂)芳基双环杂芳基衍生物,其制备方法和用作蛋白酶抑制剂的用途
CN1204327A (zh) 药用活性喹唑啉类化合物
CN1033380A (zh) 化合物
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN1524079A (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1218471A (zh) 咔啉衍生物
HK1054384B (zh) 4-嘧啶基-n-酰基-l-苯基丙氨酸类化合物
CN1082545A (zh) 咪唑并吡啶
CN1077954A (zh) 新的苯并吡喃衍生物
HK1054389A1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia
CN1152879C (zh) 萘啶衍生物
CN1071333C (zh) 喹啉衍生物
CN1081438A (zh) 咪唑衍生物及其制备方法和在治疗学上的应用
CN1571781A (zh) 4－咪唑啉－2－酮化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication